首页> 美国卫生研究院文献>Frontiers in Oncology >PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective Multicenter Open-Label Randomized Non-Comparative Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

【2h】

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective Multicenter Open-Label Randomized Non-Comparative Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

机译：Pelican-IPC 2015-016 / Oncodistinct-003：一种前瞻性多中心开放标签随机的非比较与HER2阴性炎症乳腺癌新辅助EC-PACLITAXEL方案组合的Pembrolizumab

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Frontiers in Oncology
作者
Alexandre Bertucci; François Bertucci; Christophe Zemmour; Florence Lerebours; Jean-Yves Pierga; Christelle Levy; Florence Dalenc; Julien Grenier; Thierry Petit; Marguerite Berline; Anthony Gonçalves;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：免疫检查点抑制剂;炎症乳腺癌;Neoadjuvant疗法;PDL1;Pembrolizumab;

相似文献

外文文献
中文文献

1. A prospective, multicentre, open-label, randomized phase II study of PEmbroLizumab in combination with neo-adjuvant (F)EC-paclitaxel regimen in HER2-negative Inflammatory breast CANcer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：一种预期的多方形，开放标签，随机期II研究，彭布罗耳素与新辅助剂（F）EC-PACLITAXEL方案在HER2阴性炎症乳腺癌中
2. Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：皮下施用Trastuzumab和Pertuzumab的固定剂量组合与Her2阳性早期乳腺癌中的化疗组合：III期，多中心，随机，开放标签，双臂Federica研究的主要分析
3. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer [J] . Clemens Michael R., Gladkov Oleg A., Gartner Elaina, Breast cancer research and treatment. . 2015,第1期

机译：YM155联合多西紫杉醇作为HER2阴性转移性乳腺癌患者的一线治疗的II期，多中心，开放标签，随机研究
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Prospective Phase II Multicenter Registry of Ablation after Breast Lumpectomy Added to Extend (ABLATE) Intraoperative Margins in the Treatment of Breast Cancer [D] . Klimberg, V. Suzanne. 2017

机译：乳房肿块切除术后消融的前瞻性II期多中心消融术增加了扩大（ABLATE）术中切缘在治疗乳腺癌中的作用
6. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III HER2-positive breast cancer patients: a phase 2 open-label multicenter randomized trial [O] . Liang Huang, Sheng Chen, Wentao Yang, 2015

机译：曲妥珠单抗和紫杉醇方案联合卡铂或表柔比星作为新辅助疗法对临床II-III期HER2阳性乳腺癌患者的疗效和安全性分析：第2期开放标签多中心随机试验
7. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer [O] . 2015

机译：YM155联合多西紫杉醇作为HER2阴性转移性乳腺癌患者的一线治疗的II期，多中心，开放标签，随机研究
8. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs and an NNRTI Documentation. Version 3.0 [R] . Wiznia, A., Johnson, G. M., Krogstad, P. 1999

机译：pRam-2：I / II期随机，多中心方案比较四种含有蛋白酶抑制剂，NRTI和NNRTI文献组合的抗逆转录病毒方案。版本3.0

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective Multicenter Open-Label Randomized Non-Comparative Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

著录项

相似文献

相关主题

期刊订阅